ResearchObstetricsMETHYLERGONOVINE (cas 113-42-8) maleate and the risk of myocardial ischemia and infarction

Add time:08/22/2019    Source:sciencedirect.com

ObjectiveThe purpose of this study was to examine the risks of acute coronary syndrome (ACS) and acute myocardial infarction (AMI) that are associated with methylergonovine maleate (Methergine; Novartis Pharmaceuticals Corporation, Plantation, FL) use in a large database of inpatient delivery admissions in the United States.

We also recommend Trading Suppliers and Manufacturers of METHYLERGONOVINE (cas 113-42-8). Pls Click Website Link as below: cas 113-42-8 suppliers

Prev:Case reportNew onset acute pulmonary edema after METHYLERGONOVINE (cas 113-42-8) given during cesarean delivery of a patient with undiagnosed Raynaud’s disease
Next:A sensitive LC–MS/MS method to quantify METHYLERGONOVINE (cas 113-42-8) in human plasma and its application to a pharmacokinetic study)